Actively Recruiting

Phase Not Applicable
Age: 7Years +
All Genders
ID04764357

COOLCAP Pilot Study Of Cold Cap Therapy For Prevention of Hairloss in Pediatric Patients Receiving Chemotherapy For Non-Malignant Indications and Solid Tumors

Led by St. Jude Children's Research Hospital · Updated on 2026-05-01

40

Participants Needed

1

Research Sites

52 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This research aims to evaluate whether the Paxman scalp cooling device can prevent hair loss in children and young adults receiving chemotherapy for non-cancerous conditions or solid tumors. The study focuses on assessing the safety and feasibility of scalp cooling in these patients and explores how often and how severe chemotherapy-induced hair loss occurs when using the cooling device. Participants will receive scalp cooling starting 30 to 45 minutes before each chemotherapy session, with the cooling maintained throughout the drug infusion and continuing for 120 to 180 minutes afterward. A trained staff member will apply, monitor, and remove the cooling cap, ensuring the scalp temperature stays at about 3°C (37°F). The therapy will be provided with every chemotherapy dose, following the manufacturer's instructions. During the study, participants will have photographs taken to assess hair loss, with additional photos for those with solid tumors after every two chemotherapy cycles. They will also complete questionnaires about symptoms and tolerability at different points, including baseline, during treatment, and follow-ups. Safety and feasibility will be closely monitored up to two years, and study involvement will last according to the chemotherapy schedule and follow-up assessments.

CONDITIONS

Brief Title

Study Of Cold Cap Therapy For Prevention of Hairloss in Pediatric Patients Receiving Chemotherapy For Non-Malignant Indications and Solid Tumors

Who Can Participate

Age: 7Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Receiving chemotherapy likely to cause hair loss, including specific cytotoxic agents
  • Diagnosed with a non-malignant condition or a solid tumor (non-brain tumor)
  • Age 7 years or older
  • Head circumference of 50 cm or greater
Not Eligible

You will not qualify if you...

  • Receiving chemotherapy for a blood-related cancer
  • Presence of brain or scalp tumors, scalp metastasis, or high risk of such metastasis
  • Unfit for study based on investigator or primary team opinion
  • Previous adverse reaction to the Paxman scalp cooling device
  • Cold agglutinin disease or cold urticaria
  • Unable or unwilling to provide informed consent
  • Active scalp infection or infestation at enrollment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Implementation

Duration - Duration of chemotherapy treatment

Participants receive scalp hypothermia therapy using the Paxman Scalp Cooling System during each chemotherapy infusion to help prevent hair loss. Scalp cooling starts 30-45 minutes before chemotherapy and continues for 120-180 minutes after infusion ends, with trained staff applying and monitoring the cooling cap.

A visit each time chemotherapy and scalp cooling are administered

Sample Collection

Duration - Duration of chemotherapy treatment plus 4 weeks follow-up

Photographs to assess hair condition are taken before starting scalp cooling, after every 2 chemotherapy cycles for participants with solid tumors, and at the end of the study. Patient-reported outcome questionnaires on tolerability and alopecia distress are collected at baseline, after every 2 cycles, at a 4-week follow-up, and at study end.

Visits aligned with every 2 chemotherapy cycles, plus baseline, 4-week follow-up, and end-of-study visits

Follow-up

Duration - 4 weeks after chemotherapy, with additional assessment up to 2 years

Participants are monitored for safety and feasibility of the scalp cooling device for 4 weeks after completing chemotherapy, with additional long-term feasibility assessment at the 2-year study time point.

1 visit at 4 weeks post-treatment and 1 visit at 2 years

Trial Site Locations

Total: 1 location

1

St. Jude Children's Research Hospital

Memphis, Tennessee, United States, 38105

Actively Recruiting

Loading map...

Research Team

D

Deena Levine, MD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DEVICE_FEASIBILITY

Number of Arms

1

Similar Trials

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Tria...

Areata Alopecia

Actively Recruiting

127 locations

Blinded, Randomized, Controlled Trial to Evaluate the Effica...

Androgenic Alopecia

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here